MA30691B1 - Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. - Google Patents

Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.

Info

Publication number
MA30691B1
MA30691B1 MA31580A MA31580A MA30691B1 MA 30691 B1 MA30691 B1 MA 30691B1 MA 31580 A MA31580 A MA 31580A MA 31580 A MA31580 A MA 31580A MA 30691 B1 MA30691 B1 MA 30691B1
Authority
MA
Morocco
Prior art keywords
monoclonal antibody
aluminum
pharmaceutical compositions
compositions containing
idiotypic monoclonal
Prior art date
Application number
MA31580A
Other languages
English (en)
Inventor
Jens Flemming
Karsten Groeger
Reinhard Schmitz
Stefano Manzini
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA30691B1 publication Critical patent/MA30691B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE POUR ADMINISTRATION PARENTÉRALE SOUS FORME DE VACCINS QUI COMPREND UN ANTICORPS MONOCLONAL ET UN DÉRIVÉ D'ALUMINIUM EN TANT QU'ADJUVANT.
MA31580A 2006-06-29 2009-01-22 Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. MA30691B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000163A ITFI20060163A1 (it) 2006-06-29 2006-06-29 Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio

Publications (1)

Publication Number Publication Date
MA30691B1 true MA30691B1 (fr) 2009-09-01

Family

ID=37439367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31580A MA30691B1 (fr) 2006-06-29 2009-01-22 Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.

Country Status (35)

Country Link
US (2) US20100040625A1 (fr)
EP (2) EP2040749B1 (fr)
JP (1) JP2009541448A (fr)
KR (1) KR20090024240A (fr)
CN (1) CN101478987A (fr)
AP (1) AP2009004741A0 (fr)
AR (1) AR061364A1 (fr)
AT (1) ATE502649T1 (fr)
AU (1) AU2007263690A1 (fr)
BR (1) BRPI0713343A2 (fr)
CA (1) CA2655733A1 (fr)
CL (1) CL2007001888A1 (fr)
CR (1) CR10589A (fr)
CY (1) CY1111527T1 (fr)
DE (1) DE602007013402D1 (fr)
DK (1) DK2040749T3 (fr)
EA (1) EA015543B1 (fr)
EC (1) ECSP099089A (fr)
ES (1) ES2363616T3 (fr)
HK (1) HK1126417A1 (fr)
HR (1) HRP20110413T1 (fr)
IL (1) IL196148A0 (fr)
IT (1) ITFI20060163A1 (fr)
MA (1) MA30691B1 (fr)
MX (1) MX2008016059A (fr)
NO (1) NO20090395L (fr)
PE (1) PE20080269A1 (fr)
PL (1) PL2040749T3 (fr)
PT (1) PT2040749E (fr)
RS (1) RS51683B (fr)
SI (1) SI2040749T1 (fr)
TN (1) TNSN08485A1 (fr)
UA (1) UA95806C2 (fr)
WO (1) WO2008000789A2 (fr)
ZA (1) ZA200900563B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
CA2831572C (fr) 2011-05-02 2019-11-26 Immunomedics, Inc. Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5127731B1 (fr) * 1971-05-12 1976-08-14
FR2565825B1 (fr) * 1984-06-15 1990-07-13 Centre Nat Rech Scient Vaccin contre les maladies dues a des microorganismes tels que des mycoplasmes, sa preparation et membranes de microorganismes en tant que principe actif
EP0700305B1 (fr) * 1993-05-27 2000-01-26 Wagner, Uwe, Dr.med. Anticorps monoclonaux anti-ca125 et antiidiotypiques, et compositions pharmaceutiques les contenant
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio

Also Published As

Publication number Publication date
WO2008000789A3 (fr) 2008-02-28
CN101478987A (zh) 2009-07-08
ES2363616T3 (es) 2011-08-10
TNSN08485A1 (en) 2010-04-14
EP2228073A1 (fr) 2010-09-15
MX2008016059A (es) 2009-01-15
CR10589A (es) 2009-03-30
HRP20110413T1 (hr) 2011-07-31
RS51683B (en) 2011-10-31
EA200900085A1 (ru) 2009-06-30
KR20090024240A (ko) 2009-03-06
DE602007013402D1 (de) 2011-05-05
BRPI0713343A2 (pt) 2012-03-13
HK1126417A1 (en) 2009-09-04
CL2007001888A1 (es) 2008-04-18
US20090104184A1 (en) 2009-04-23
UA95806C2 (ru) 2011-09-12
DK2040749T3 (da) 2011-06-14
CA2655733A1 (fr) 2008-01-03
PL2040749T3 (pl) 2011-09-30
ATE502649T1 (de) 2011-04-15
US20100040625A1 (en) 2010-02-18
ITFI20060163A1 (it) 2006-09-28
PT2040749E (pt) 2011-06-30
AP2009004741A0 (en) 2009-02-28
JP2009541448A (ja) 2009-11-26
EP2040749A2 (fr) 2009-04-01
NO20090395L (no) 2009-01-27
WO2008000789A2 (fr) 2008-01-03
IL196148A0 (en) 2011-08-01
AR061364A1 (es) 2008-08-20
ZA200900563B (en) 2010-03-31
EP2040749B1 (fr) 2011-03-23
PE20080269A1 (es) 2008-05-09
CY1111527T1 (el) 2015-08-05
ECSP099089A (es) 2009-02-27
SI2040749T1 (sl) 2011-06-30
EA015543B1 (ru) 2011-08-30
AU2007263690A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA30671B1 (fr) Vaccins contre le paludisme
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
MA37610B1 (fr) Formulations de testostérone proliposomales
MA34313B1 (fr) Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan
MA33295B1 (fr) Nouvelle formulation de diclofénac
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
EA201070827A1 (ru) Способы и композиции для перорального введения белковых и пептидных терапевтических средств
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA34296B1 (fr) Composition retard injectable antipsychotique
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
MA31684B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
PE20090216A1 (es) Compuestos triazolil aminopirimidina